Related Experiment Videos
[Laboratory and clinical studies of cefodizime in pediatric field]
T Nishimura1, K Tabuki, S Aoki
1Department of Pediatrics, Osaka Medical College.
Insights
Cefodizime (CDZM) demonstrated favorable pharmacokinetics and clinical efficacy in pediatric bacterial infections. This cephalosporin antibiotic showed good to excellent results in most cases with minimal adverse effects.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Context:
- Cefodizime (CDZM) is a cephalosporin antibiotic investigated for pediatric use.
- Bacterial infections in children pose significant health challenges requiring effective treatment options.
Purpose:
- To evaluate the pharmacokinetics and clinical effectiveness of cefodizime (CDZM) in pediatric patients.
- To assess the safety profile of CDZM in children with various bacterial infections.
Summary:
- Laboratory and clinical studies were conducted on cefodizime (CDZM).
- Pharmacokinetic parameters including serum levels and half-lives were determined after intravenous infusion at different doses (10, 20, 40 mg/kg).
- CDZM was administered to 28 pediatric patients with infections such as pneumonia, enteritis, and urinary tract infections, yielding excellent or good results in 20 cases.
Impact:
- Cefodizime (CDZM) exhibits promising pharmacokinetic properties and therapeutic efficacy for treating pediatric bacterial infections.
- The study suggests CDZM is a viable treatment option with a generally good safety profile in the pediatric population.
Abstract:
We have carried our laboratory and clinical studies on cefodizime (CDZM, THR-221). The results were summarized as follows. CDZM was given by 30-minute drip infusion to 2 children at a single dose of 10 mg/kg and to 2 children at a single dose of 20 mg/kg and to 3 children at a single dose of 40 mg/kg. After the 30-minute drip infusion, mean serum levels of CDZM obtained for the 3 dose levels were 76.16 +/- 5.52 micrograms/ml, 170.49 +/- 16.70 micrograms/ml, 270.01 +/- 50.44 micrograms/ml at the end of injection, respectively, and serum half-lives were 2.03 +/- 0.78 hours, 2.03 +/- 0.38 hours, 2.28 +/- 0.30 hours, respectively. The mean urinary excretion rate of CDZM were 83.3 +/- 22.3%, 73.1 +/- 13.9%, 51.1 +/- 8.5% in the first 8 hours after the 30-minute drip infusion of 10 mg/kg, 20 mg/kg, 40 mg/kg, 40 mg/kg, respectively. Treatment with CDZM was made in 28 cases of pediatric bacterial infections; 5 cases of tonsillitis, 2 cases of bronchitis, 10 cases of pneumonia, 6 cases of enteritis, 3 cases of urinary tract infection and 1 case each of maxillary sinusitis and laryngitis. Results obtained were excellent in 13 cases, good in 7 cases, fair in 2 cases, poor in 6 cases. No significant side effect due to the drug was observed except one case of thrombocytosis and 2 cases each of elevated GOT and elevated GOT and GPT.